Edition:
United Kingdom

People: Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

22.38USD
17 Sep 2019
Change (% chg)

$-0.84 (-3.62%)
Prev Close
$23.22
Open
$22.95
Day's High
$23.20
Day's Low
$22.02
Volume
450,668
Avg. Vol
227,387
52-wk High
$36.12
52-wk Low
$16.97

Enright, Patrick 

Mr. Patrick G. Enright is Independent Director of the Company. He has served as a member of our Board since April 2013. Mr. Enright is a founder of Longitude Capital, a venture capital firm focused on investments in pharmaceutical and medical technology companies, and has served as its Managing Director since 2006. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital investment firm, where he co-led the life sciences investment practice. He currently serves on the board of directors and as a member of the audit and compensation committees of Jazz Pharmaceuticals plc, a pharmaceutical company. Mr. Enright previously served on the board of directors and as a member of the audit committee of Corcept Therapeutics Incorporated, a pharmaceutical company, and as a member of the board of directors and as chair of the audit committee of Esperion Therapeutics, Inc., a pharmaceutical company. Mr. Enright is also on the board of several privately-held companies. Mr. Enright received a B.S. in Biological Sciences from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania. We believe that Mr. Enright is qualified to serve on our Board due to his experience serving on the board of directors of clinical-stage biotechnology companies and his investment experience in the life sciences industry.

Basic Compensation

Total Annual Compensation, USD 252,789
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 252,789

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --